Logo

XBIO

Xenetic Biosciences, Inc.

XBIO

Xenetic Biosciences, Inc. • NASDAQ
$2.58 ▲ 2.38% (+0.06)
Market Cap $3.98 M
52w High $13.93
52w Low $2.20
Dividend Yield 0%
P/E -1.26
Volume 241
Outstanding Shares 1.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.027M ▲ $1.572M ▲ $-509.939K ▲ -49.655% ▲ $-0.33 ▲ $-523.176K ▲
Q2-2025 $589.897K ▼ $1.314M ▼ $-688.703K ▲ -116.75% ▲ $-0.45 ▲ $-724.412K ▲
Q1-2025 $593.261K ▼ $1.536M ▼ $-903.141K ▲ -152.233% ▲ $-0.59 ▲ $-942.409K ▲
Q4-2024 $648.82K ▲ $1.748M ▲ $-1.055M ▼ -162.529% ▼ $-0.68 ▼ $-1.099M ▼
Q3-2024 $614.243K $1.114M $-436.671K -71.091% $-0.28 $-499.473K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.122M ▼ $5.068M ▼ $1.112M ▲ $3.956M ▼
Q2-2025 $4.78M ▼ $5.354M ▼ $903.43K ▲ $4.45M ▼
Q1-2025 $5.164M ▼ $5.791M ▼ $667.927K ▼ $5.123M ▼
Q4-2024 $6.166M ▼ $6.901M ▼ $894.263K ▼ $6.007M ▼
Q3-2024 $6.84M $8.046M $1.009M $7.037M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-509.939K ▲ $-658.247K ▼ $0 $0 $-658.247K ▼ $-658.25K ▼
Q2-2025 $-688.703K ▲ $-383.83K ▲ $0 $0 $-383.83K ▲ $-383.83K ▲
Q1-2025 $-903.141K ▲ $-1.002M ▼ $0 $0 $-1.002M ▼ $-1.002M ▼
Q4-2024 $-1.055M ▼ $-673.992K ▼ $0 $0 $-673.992K ▼ $-673.992K ▼
Q3-2024 $-436.671K $-459.037K $0 $0 $-459.037K $-459.037K

Revenue by Products

Product Q4-2020Q1-2021Q2-2021Q3-2021
Royalty Revenue
Royalty Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲
RoyaltyRevenueMember
RoyaltyRevenueMember
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Xenetic is still a classic early‑stage biotech story: no product revenue yet and ongoing losses. All the activity is on the research and development side rather than on selling approved drugs. Reported losses per share have been large but have narrowed over time, although this is heavily influenced by repeated reverse stock splits rather than underlying profitability. Overall, the income statement reflects a company that is investing in science without yet having a commercial engine to support it.

Balance Sheet

Balance Sheet The balance sheet is extremely small and almost entirely made up of cash, with no financial debt reported. That keeps things simple and avoids interest burden, but also highlights how limited the company’s financial resources are relative to the scale of cancer drug development. Equity essentially mirrors the cash on hand, pointing to a business funded by shareholders rather than by retained profits or borrowings.

Cash Flow

Cash Flow Cash flow data suggest minimal capital spending and no internal cash generation from operations, which is normal for a pre‑revenue biotech. The company appears to run a lean cost base, but it still depends on outside funding or partnership payments to sustain R&D. Until there is either a significant partnership, milestone income, or an approved product, cash flow will remain a key vulnerability and likely a recurring concern.

Competitive Edge

Competitive Edge Xenetic is trying to build a niche in a relatively new corner of cancer biology: targeting neutrophil extracellular traps (NETs) to make tumors more vulnerable to treatment. This is a focused and less crowded space, especially on the oncology side, which gives the company some differentiation. Its technology is designed to work alongside existing cancer drugs rather than replace them, which could broaden its potential use if proven. On the other hand, Xenetic is tiny, preclinical, and competing in a field dominated by much larger, better‑funded players, so its bargaining power and ability to move quickly are constrained.

Innovation and R&D

Innovation and R&D Innovation is the main asset here. The DNase platform aims to break down the tumor’s protective environment and boost the impact of immunotherapies, chemotherapy, and CAR‑T cell treatments. Early lab data are encouraging but still preclinical, meaning there is a long road of trials and risk ahead. The PolyXen drug‑delivery platform and the personalized XCART cell therapy concept add optionality and are supported by partnerships with major institutions and a large pharma company. Overall, the pipeline is scientifically interesting and diversified for a company this small, but entirely unproven in humans so far.

Summary

Xenetic Biosciences is an ultra‑early, pre‑revenue oncology platform company with an innovative scientific angle but a very thin financial foundation. The story is almost entirely about future potential: can the DNase and other platforms translate promising lab results into meaningful clinical data and partnerships? The absence of revenue, small cash base, and history of reverse splits underline both financing risk and high dependence on external support. For anyone following the company, the key things to watch are clinical trial initiation and results, new or expanded collaborations, and how effectively the company manages its limited capital while progressing its science.

NEWS

November 19, 2025 · 8:45 AM UTC

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Read more

November 13, 2025 · 8:45 AM UTC

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Read more

October 10, 2025 · 9:30 AM UTC

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Read more